如何治疗红细胞生成性原卟啉病与X连锁原卟啉病
红细胞生成性原卟啉病(EPP)由亚铁螯合酶表达降低导致原卟啉IX蓄积,引起严重皮肤光敏和少数患者致死性肝病;X连锁原卟啉病(XLP)由δ-氨基乙酰丙酸合酶2活性增加所致,临床相似。本文通过3例患者案例,讨论光敏处理、铁缺乏管理和肝衰竭认识等关键治疗考虑。
要点
- EPP由亚铁螯合酶表达降低致原卟啉IX蓄积,XLP由δ-氨基乙酰丙酸合酶2活性增加所致。
- 原卟啉病管理传统以避光为中心,新型疗法近期已获批或正在研发。
- 治疗需关注光敏处理、铁缺乏管理及肝衰竭识别三方面。
核心结论
- 原卟啉病的管理传统以避光为中心,新型疗法近期已获批或正在研发,将改变治疗格局。
研究设计与样本
- 本文为综述,通过3例患者案例讨论原卟啉病的关键治疗考虑。
主要发现
- EPP由亚铁螯合酶表达降低导致原卟啉IX蓄积,引起严重疼痛性皮肤光敏和少数患者致死性肝病。
- XLP由δ-氨基乙酰丙酸合酶2活性增加所致,临床与EPP相似,也引起原卟啉蓄积。
- 3例患者案例突出光敏处理、原卟啉病中铁缺乏管理及肝衰竭认识等关键治疗考虑。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Erythropoietic protoporphyria (EPP) is an inherited cutaneous porphyria caused by reduced expression of ferrochelatase, the enzyme that catalyzes the final step in heme biosynthesis. The resultant accumulation of protoporphyrin IX leads to severe, painful cutaneous photosensitivity, as well as potentially life-threatening liver disease in a small percentage of patients. X-linked protoporphyria (XLP) is clinically similar to EPP but results from increased activity of δ-aminolevulinic acid synthase 2, the first step in heme biosynthesis in the bone marrow, and also causes protoporphyrin accumulation. Although historically the management of EPP and XLP (collectively termed protoporphyria) centered around avoidance of sunlight, novel therapies have recently been approved or are in development, which will alter the therapeutic landscape for these conditions. We present 3 patient cases, highlighting key treatment considerations in patients with protoporphyria, including (1) approach to photosensitivity, (2) managing iron deficiency in protoporphyria, and (3) understanding hepatic failure in protoporphyria.
引用
- Leaf RK, Dickey AK. How I treat erythropoietic protoporphyria and X-linked protoporphyria. Blood. 2023. PMID: 36898083. doi:10.1182/blood.2022018688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。